Neil W A McGowan
Overview
Explore the profile of Neil W A McGowan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brennan P, MacMillan M, Manship T, Moroni F, Glover A, Troland D, et al.
Nat Med
. 2025 Jan;
PMID: 39794616
Cirrhosis is a major cause of morbidity and mortality; however, there are no approved therapies except orthotopic liver transplantation. Preclinical studies showed that bone-marrow-derived macrophage injections reduce inflammation, resolve fibrosis...
2.
Cooper R, Sutherland C, Smith L, Cowan G, Barnett M, Mitchell D, et al.
Front Immunol
. 2024 Jul;
15:1412211.
PMID: 39011042
Adoptive immunotherapy with Epstein-Barr virus (EBV)-specific T cells is an effective treatment for relapsed or refractory EBV-induced post-transplant lymphoproliferative disorders (PTLD) with overall survival rates of up to 69%. EBV-specific...
3.
Brennan P, MacMillan M, Manship T, Moroni F, Glover A, Graham C, et al.
BMJ Open
. 2021 Nov;
11(11):e053190.
PMID: 34750149
Introduction: Liver cirrhosis is a growing global healthcare challenge. Cirrhosis is characterised by severe liver fibrosis, organ dysfunction and complications related to portal hypertension. There are no licensed antifibrotic or...
4.
Thirlwell K, Colligan D, Mountford J, Samuel K, Bailey L, Cuesta-Gomez N, et al.
Cytotherapy
. 2020 Aug;
22(12):762-771.
PMID: 32828673
Background Aims: Mesenchymal stromal cells (MSCs) isolated from various tissues are under investigation as cellular therapeutics in a wide range of diseases. It is appreciated that the basic biological functions...
5.
Forbes S, Bond A, Thirlwell K, Burgoyne P, Samuel K, Noble J, et al.
Sci Transl Med
. 2020 Jan;
12(526).
PMID: 31941825
Islet transplantation is an efficacious therapy for type 1 diabetes; however, islets from multiple donor pancreata are required, and a gradual attrition in transplant function is seen. Here, we manufactured...
6.
Zaiss M, Hall C, McGowan N, Babb R, Devlia V, Lucas S, et al.
ACR Open Rheumatol
. 2019 Nov;
1(6):382-393.
PMID: 31777818
Objective: The association between inflammation and dysregulated bone remodeling is apparent in rheumatoid arthritis and is recapitulated in the human tumor necrosis factor transgenic (tg) mouse model. We investigated whether...
7.
Moroni F, Dwyer B, Graham C, Pass C, Bailey L, Ritchie L, et al.
Nat Med
. 2019 Oct;
25(10):1560-1565.
PMID: 31591593
Therapies to reduce liver fibrosis and stimulate organ regeneration are urgently needed. We conducted a first-in-human, phase 1 dose-escalation trial of autologous macrophage therapy in nine adults with cirrhosis and...
8.
Campbell J, Ahmad S, Agrawal A, Bienek C, Atkinson A, McGowan N, et al.
Stem Cells Transl Med
. 2019 Jan;
8(4):323-331.
PMID: 30688407
Limbal stem cell deficiency (LSCD) is a disease resulting from the loss or dysfunction of epithelial stem cells, which seriously impairs sight. Autologous limbal stem cell transplantation is effective in...
9.
McGowan N, Campbell J, Mountford J
Methods Mol Biol
. 2017 Oct;
1698:285-292.
PMID: 29076098
Blood transfusion is a mainstay of modern medical practice. In many parts of the world the use of this life-saving therapy is hampered by issues of supply and the potential...
10.
Fraser A, Pass C, Burgoyne P, Atkinson A, Bailey L, Laurie A, et al.
Cytotherapy
. 2017 Jul;
19(9):1113-1124.
PMID: 28673774
Background Aims: Autologous macrophage therapy represents a potentially significant therapeutic advance for the treatment of severe progressive liver cirrhosis. Administration of macrophages has been shown to reduce inflammation and drive...